{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:52:24Z","timestamp":1785851544725,"version":"3.56.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.critrevonc.2016.02.013","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T12:43:01Z","timestamp":1456663381000},"page":"12-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta -analysis of published trials"],"prefix":"10.1016","volume":"101","author":[{"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bonetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Cappelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2016.02.013_bib0005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.bjc.6604904","article-title":"CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer","volume":"100","author":"Ang","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"23","key":"10.1016\/j.critrevonc.2016.02.013_bib0010","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/era.11.196","article-title":"Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer","volume":"12","author":"Bedoya","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1470-2045(09)70229-3","article-title":"Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target","volume":"10","author":"Chen","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0030","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"March (5)","key":"10.1016\/j.critrevonc.2016.02.013_bib0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1158\/1078-0432.CCR-13-2436","article-title":"Phase I\/II trial of orteronel (TAK-700)\u2fffan investigational 17,20-lyase inhibitor\u2fffin patients with metastatic castration-resistant prostate cancer","volume":"20","author":"Dreicer","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"March (1)","key":"10.1016\/j.critrevonc.2016.02.013_bib0045","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.2014.56.5119","volume":"33","author":"Fizazi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0050","doi-asserted-by":"crossref","unstructured":"Fizazi K., Scher H.I., Molina A., Logothetis C.J., Chi K.N., Jones R.J., Staffurth J.N., North S., Vogelzang N.J., Saad F., Mainwaring P., Harland S., Goodman O.B. Jr., Sternberg C.N., Li J.H., Kheoh T., Haqq C.M., de Bono J.S. COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 October;13(10):983-92. Erratum in: Lancet Oncol. 2012 November;13(11):e464. Lancet Oncol. 2014 August;15(9):e365.","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.critrevonc.2016.02.013_bib0060","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s40265-013-0150-z","article-title":"Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer","volume":"73","author":"Hoy","year":"2013","journal-title":"Drugs"},{"issue":"July (10)","key":"10.1016\/j.critrevonc.2016.02.013_bib0065","first-page":"00621","article-title":"The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer","volume":"15","author":"Iacovelli","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.02.013_bib0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0080","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.bmc.2011.08.066","article-title":"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer","volume":"19","author":"Kaku","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0085","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res."},{"issue":"June (16)","key":"10.1016\/j.critrevonc.2016.02.013_bib0090","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(15)70033-1","article-title":"Sequencing of agents in castration-resistant prostate cancer","volume":"16","author":"Lorente","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.02.013_bib0095","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/annonc\/mdt010","article-title":"European cancer mortality predictions for the year 2013","volume":"24","author":"Malvezzi","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0100","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"PRISMA Group. PRISMA Group. preferred reporting items for systematic reviews and meta-analyses: the prisma statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"October (5)","key":"10.1016\/j.critrevonc.2016.02.013_bib0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/COC.0b013e3182a790ce","article-title":"Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors","volume":"38","author":"Procopio","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"issue":"May (21)","key":"10.1016\/j.critrevonc.2016.02.013_bib0110","first-page":"6","article-title":"The third line of treatment for metastatic prostate cancer patients: option or strategy?","volume":"15","author":"Roviello","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"Febuary (2)","key":"10.1016\/j.critrevonc.2016.02.013_bib0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.02.013_bib0120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2016.02.013_bib0125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1470-2045(15)70027-6","article-title":"Wit R; ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial","volume":"16","author":"Saad","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3\u2fff5","key":"10.1016\/j.critrevonc.2016.02.013_bib0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsbmb.2012.01.001","article-title":"Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys","volume":"129","author":"Yamaoka","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816300373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816300373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T16:22:18Z","timestamp":1536942138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816300373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":26,"alternative-id":["S1040842816300373"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.02.013","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}